- Advertisement -

Patients with advanced pancreatic cancer now have access to the new FDA approved drug, Onivyde that produced significant overall survival rates in an international clinical study conducted in part by researchers at Honor Health Research Institute and the Translational Genomics Research Institute.

“Results from our clinical trial research showed a patient survival rate of nearly two more months without decreasing the quality of life compared to the other treatments tested, ” said Gayle Jameson, principal investigator,

“Invariably pancreatic cancer progresses at some point and we don’t have a universal standard of what to do next.  In this disease, two months of survival is a game changer for treating advanced pancreatic cancer and gives patients hope.”
Only about 1 in 4 patients survive more than one year after diagnosis, and less than 10 percent survivor more than five years.

- Advertisement -

Onivyde will be used as part of a combination regimen with a two-drug chemotherapy. It was approved to treat patients with pancreatic cancer that progressed after treatment with a different chemotherapy.

The large, randomized clinical trial that evaluated the new drug, the NAPOLI-1 (NAnoliPOsomaL Irinotecan), evaluated patients enrolled at more than 100 sites in North America, South America, Europe, Asia and Australia.

The 417 patients in the study all had metastatic pancreatic cancer that was previously and treated with the traditional standard-of-care, gemcitabine-based therapy.

Symptoms of pancreatic cancer usually do not appear until the cancer is in its late stages, making it difficult to treat. Once the disease spreads to other parts of the body, most patients are not candidates for surgery and receive chemotherapy as their primary treatment.

 

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.